Self-activation in Individuals With and Without Nicotine Dependence
NCT ID: NCT03170258
Last Updated: 2024-09-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
46 participants
INTERVENTIONAL
2018-02-28
2022-07-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence
NCT00672256
Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation
NCT02927847
Nicotine Withdrawal and Reward Processing: Connecting Neurobiology to Real-world Behavior
NCT03840694
A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers
NCT00901459
Neuroimaging Attentional Impairment During Abstinence
NCT00692406
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Assess the ability of adults with and without nicotine dependence (ND) to activate reward-related brain regions (e.g., ventral tegmental area (VTA), striatum, prefrontal cortex).
2. Evaluate whether fMRI and/or EEG neurofeedback improves the ability to increase reward-related brain activation in individuals with and without ND.
3. Examine the relationship between activation of reward-related regions via neurofeedback and dopamine availability (as assessed genetically).
4. Examine the effects of neurofeedback on clinically relevant outcomes, including reward responsivity and smoking related behaviors.
Procedure:
Prior to coming to a screening visit, all potential participants will undergo a phone pre-screening using an IRB approved phone script to pre-identify potentially eligible participants and to potentially decrease screen fail rate. These interested potential participants call or email the site in response to advertisements. The pre-screening will take place via phone. Participants who pass the pre-screening will complete some or all of the following visits: Screening, Camera Return Visit, Real-Time Neurofeedback Visit, Follow-up Phone Call/Debriefing.
Screening Visit:
Participants with nicotine dependence who pass the pre-screen will come to the lab at Duke to complete additional screening. All participants will undergo informed consent and those with ND will complete a urine drug screen. Participants who pass the urine drug screen (results are provided immediately) will complete questionnaires assessing mood, reward processing, and smoking behaviors.
Some participants may also be given a camera to use to capture pictures of personalized rewarding objects (e.g., picture of their pet, favorite book, favorite food). Participants may be loaned the camera for a period of 1-2 weeks to capture pictures of rewarding objects. We will instruct participants that the camera is to be used exclusively for capturing pictures for the study and not for personal use. Some participants may not be asked to take their own pictures for the study protocol and may simply be shown neutral or positive pictures/images/objects provided by the experimenters (e.g., shapes, pictures, etc.). Note, no aversive images will be shown to participants.
Camera Return Visit:
Participants who were loaned a camera will be asked to come to the lab at Duke to return the camera. The experimenters will ensure that enough pictures have been acquired to use during the experiment. Participants will be given guidelines about what types of pictures are required for the study. Participants are also free to provide photos they already have by uploading them to a secure website or brining them in on a device (e.g., thumbdrive).
Participants may also be asked to view and rate the pictures they provide along with neutral and positive images we provide (e.g., puppy, flower) on dimensions such as valence and arousal.
Real-Time Neurofeedback Visit:
Eligible participants will be scheduled for an fMRI and/or EEG session to assess and measure the ability to self-activate reward-related regions. The fMRI session will be conducted at the Duke Brain Imaging and Analysis Center (BIAC) and/or the UNC Biomedical Research Imaging Center (BRIC). Female participants will have a urine pregnancy test prior to fMRI scanning; the test will be verified to be negative in order to proceed with the scanning session. The EEG sessions will take place in private testing space in the Levine Science Research Center or the BIAC.
Participants may complete some or all of the following tasks: Reward Activation Task, Passive Viewing Task, and Reward Learning Task. All of these tasks aim to assess how adults can learn to interact with neurofeedback provided from an fMRI or EEG system. The tasks vary slightly from each other in terms of stimuli used (personalized pictures, images provided by the experimenters, feedback display, etc.). It may be possible that we will not be able to get a good EEG signal for some participants, based on equipment error or head size. If this occurs, participants will be debriefed. We will be sure to emphasize there was no error on the participant's part, and that sometime the signal is difficult to acquire for a variety of reasons.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Reward-related Brain Region Feedback
Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
Neurofeedback (from fMRI and/or EEG)
During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
Noise Control
Participants in this group will receive sham neurofeedback. Participants will be debriefed at the end of the study.
Neurofeedback (from fMRI and/or EEG)
During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neurofeedback (from fMRI and/or EEG)
During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Right handed
3. In good general health
4. Male or Female
5. For ND individuals: Self-reported smoking ≥ 5 combustible cigarettes per day
6. For ND individuals: Afternoon expired CO concentration of ≥ 8 ppm
7. For ND individuals: Is willing and able to abstain from smoking for a few hours
Exclusion Criteria
2. Current or past 6 month use of prescription medications for psychiatric conditions (e.g., depression, anxiety)
3. Current or past 6 month diagnosis of anxiety, bipolar disorder, depression, OCD, schizophrenia, psychosis, or personality disorder.
4. Current substance abuse or dependence or history within the last 6 months (other than nicotine for ND individuals)
5. For ND individuals: Positive drug test for anything other than marijuana
6. For ND individuals: Currently on nicotine replacement therapy
7. For ND individuals: Individuals who role their own cigarettes
8. For ND individuals: Daily cannabis use
9. For ND individuals: Consume more than 21 alcoholic drinks per week
10. For ND individuals: Use harder drugs (e.g., cocaine, methamphetamine) more than 10 times per year
11. For ND individuals: Currently taking medication that directly acts on the dopamine system (e.g., L-DOPA).
12. Inability to understand written and/or spoken English language
13. For MRI subjects: Claustrophobia or other contraindications to MRI scanning
14. For MRI subjects: If female, pregnancy as determined by urine pregnancy test on the day of MRI scanning
15. For MRI subjects: Presence of any metal in the body (e.g., implant, non-removable piercing, metal IUD)
16. For MRI subjects: Head injury resulting in loss of consciousness
17. For MRI subjects: Worked with metal (e.g., welding) or had an injury to the eye involving metal
18. For MRI subjects: Weigh more than 250 pounds
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Brain & Behavior Research Foundation
OTHER
National Center for Advancing Translational Sciences (NCATS)
NIH
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
R. Alison Adcock, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Duke University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Cognitive Neuroscience
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24393
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
Pro00081458
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.